Valuation: Cipher Pharmaceuticals Inc.

Market Cap 340M 243M 217M 201M 182M 23.1B 346M 2.42B 956M 12.1B 913M 894M 38.15B P/E 2026 *
11.9x
P/E 2027 * 11x
Enterprise Value 340M 243M 217M 201M 182M 23.1B 346M 2.42B 956M 12.1B 913M 894M 38.15B EV / Sales 2026 *
4.8x
EV / Sales 2027 * 4.18x
Free-Float
57.46%
Yield 2026 *
-
Yield 2027 * -
1 day-1.90%
1 week+1.06%
Current month-1.90%
1 month-6.17%
3 months-18.55%
6 months-26.27%
Current year-11.09%
1 week 13.25
Extreme 13.25
13.81
1 month 13.25
Extreme 13.25
14.05
Current year 13.25
Extreme 13.25
20.56
1 year 12.48
Extreme 12.48
20.56
3 years 4.3
Extreme 4.3
20.56
5 years 1.54
Extreme 1.54
20.56
10 years 0.38
Extreme 0.38
20.56
Manager TitleAgeSince
Chief Executive Officer - 2019-07-28
Director of Finance/CFO - 2024-08-09
Director of Finance/CFO - 2022-08-14
Director TitleAgeSince
Chairman - 2019-06-11
Director/Board Member 78 2023-06-20
Director/Board Member - 2023-06-20
Date Insider Type Main position Quantity % Market Cap. Importance
9/30/26 TaxCompany -133,245 0.5243%
9/30/26 TaxCompany 133,245 0.5243%
9/29/26 Option

Director

5,000 0.0197%
Change 5-day change 1-year change 3-year change Capi.($)
-1.90%+1.06%-7.34%+203.63% 241M
-2.54%+1.31%+55.10%+120.84% 1,165B
-1.42%+3.23%+37.07%+74.26% 645B
+0.16%+0.08%+25.14%+97.36% 504B
-0.31%+3.09%+43.92%+64.55% 380B
-1.34%-0.47%+66.63%+40.56% 363B
-0.68%+2.65%+22.46%+51.48% 297B
-1.20%+3.04%+2.62%+26.97% 269B
-1.79%+1.57%+49.97%+60.87% 237B
-0.73%-0.10%+29.24%+101.19% 195B
Average -0.79%+2.03%+32.48%+84.17% 405.57B
Weighted average by Cap. -0.25%+2.67%+41.07%+82.29%

Financials

2026 *2027 *
Net sales 70.85M 50.66M 45.24M 41.79M 37.87M 4.81B 72.02M 503M 199M 2.52B 190M 186M 7.94B 81.35M 58.16M 51.94M 47.98M 43.48M 5.52B 82.7M 577M 229M 2.89B 218M 214M 9.12B
Net income 27.7M 19.8M 17.68M 16.34M 14.81M 1.88B 28.16M 197M 77.84M 985M 74.32M 72.74M 3.11B 31.76M 22.71M 20.28M 18.73M 16.98M 2.16B 32.29M 225M 89.25M 1.13B 85.22M 83.41M 3.56B
Net Debt - -
Projected Income Statement - Annual - Cipher Pharmaceuticals Inc.
Logo Cipher Pharmaceuticals Inc.
Cipher Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company acquires products, manages the required clinical development and regulatory approval process, and markets those products either directly or indirectly in Canada, the United States and South America. The Company's product categories include dermatology, hospital acute care, out‑licensed, and specialty medicine. Its dermatology products include Actikerall, Epuris, Vaniqa and Natroba. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Absorica (isotretinoin) is an oral retinoid. Durela, its specialty medicine, is an opioid analgesic indicated for the management of moderate to moderately severe pain in adults who require continuous treatment for several days or more. Its pipeline products include Piclidenoson CF-101, MOB-015 and DTR-001.
Employees
5
Date Price Change Volume
26-10-23 $13.39 -1.90% 3,809
26-10-22 $13.65 +2.55% 6,986
26-10-21 $13.31 +0.45% 2,988
26-10-20 $13.25 0.00% 11,571
26-10-19 $13.25 0.00% 8,408
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Cipher Pharmaceuticals Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
13.39CAD
Average target price
19.45CAD
Spread / Average Target
+45.26%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Cipher Pharmaceuticals Inc.